Population pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC)

被引：0
|
作者：
Jansen, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Vernaz-Gris, M. [1 ,2 ,3 ,4 ,5 ,6 ]
DesJardins, C. [1 ,2 ,3 ,4 ,5 ,6 ]
Wong, N. [1 ,2 ,3 ,4 ,5 ,6 ]
Campone, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Cortes, J. [1 ,2 ,3 ,4 ,5 ,6 ]
Wanders, J. [1 ,2 ,3 ,4 ,5 ,6 ]
Shuster, D. [1 ,2 ,3 ,4 ,5 ,6 ]
Fuseau, E. [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Eisai Ltd, London, England
[2] EMF Consulting, Aix En Provence, France
[3] Eisai Res Inst, Andover, MA USA
[4] Ctr Rene Gauducheau, St Herblain, France
[5] Vall Hebron Univ Hosp, Barcelona, Spain
[6] Eisai Med Res, Ridgfield Pk, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2524
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Eribulin mesylate versus eribulin plus anlotinib in patients with advanced or metastatic breast cancer: Results of a phase II study.
    Liu, Liping
    Hu, Zhe-Yu
    Xie, Ning
    Yang, Xiaohong
    Xiao, Huawu
    Li, Jing
    Tian, Can
    Wu, Hui
    Lu, Jun
    Gao, Jianxiang
    Hu, Xuming
    Cao, Min
    Shui, Zhengrong
    Liu, Bingliang
    Ouyang, Quchang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses
    Kaufman, Peter Andrew
    Cortes, Javier
    Awada, Ahmad
    Yelle, Louise
    Perez, Edith A.
    Wanders, Jantien
    Olivo, Martin S.
    He, Yi
    Dutcus, Corina
    Twelves, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Efficacy and toxicity profile of eribulin mesylate for metastatic breast cancer (MBC) patients (pts) in the routine clinic: A French observational study.
    Patsouris, Anne
    Linot, Benjamin
    Robert, Marie
    Gourmelon, Carole
    Campone, Mario
    Brunot, Angelique
    Lefeuvre-Plesse, Claudia
    Martin, Jerome
    Marquis, Adele
    Bourgeois, Hugues Pierre
    Som, Mickael
    Desclos, Herve
    Tredan, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] POPULATION PHARMACOKINETIC (PPK) MODELING OF AXITINIB IN PATIENTS WITH METASTATIC OR UNRESECTABLE LOCALLY ADVANCED THYROID CANCER.
    Chang, A.
    Pithavala, Y. K.
    Bycott, P.
    Ingrosso, A.
    Ruiz, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S67 - S67
  • [25] POPULATION PHARMACOKINETIC-PHARMACODYNAMIC (PK/PD) ANALYSIS OF SAFETY AND EFFICACY OF ERIBULIN IN METASTATIC OR LOCALLY ADVANCED BREAST CANCER PATIENTS
    Gupta, A.
    Mould, D. R.
    Reyderman, L.
    Wanders, J.
    Shuster, D. E.
    Hussein, Z.
    Jansen, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 111 - 111
  • [26] Absolute lymphocyte count (ALC) is a predictor of eribulin benefit in advanced or metastatic breast cancer (MBC)
    Cortes, Javier
    Manuel Perez-Garcia, Jose
    Nomoto, Kenichi
    Alexis, Karenza
    Saito, Kenichi
    Yoshimura, Yuta
    Muramoto, Kenzo
    Miyoshi, Yasuo
    CANCER RESEARCH, 2020, 80 (04)
  • [27] Eribulin Mesylate improving survival outcomes of metastatic breast cancer
    Nakai, M.
    Suzuki, M.
    Kurita, T.
    Yanagihara, K.
    Takei, H.
    BREAST, 2017, 32 : S67 - S67
  • [28] QUALITY OF LIFE (QOL) ASSESSMENT IN WOMEN WITH LOCALLY ADVANCED (LA) OR METASTATIC BREAST CANCER (MBC): RESULTS OF A PHASE II TRIAL WITH ERIBULIN
    Simons, W. R.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 120 - 120
  • [29] ERIBULIN MESYLATE (E7389) IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH AN ANTHRACYCLINE AND A TAXANE: PHASE II NEUROPATHY DATA
    Cortes, J. A.
    Campone, M.
    Twelves, C.
    Vahdat, L. T.
    Blum, J. L.
    Rivera, R. R.
    Shuster, D. E.
    Wanders, J.
    Fang, F.
    Allison, M. A. K.
    ANNALS OF ONCOLOGY, 2008, 19 : 70 - 70
  • [30] Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine
    Cortes, Javier
    Vahdat, Linda
    Blum, Joanne L.
    Twelves, Chris
    Campone, Mario
    Roche, Henri
    Bachelot, Thomas
    Awada, Ahmad
    Paridaens, Robert
    Goncalves, Anthony
    Shuster, Dale E.
    Wanders, Jantien
    Fang, Fang
    Gurnani, Renuka
    Richmond, Elaine
    Cole, Patricia E.
    Ashworth, Simon
    Allison, Mary Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) : 3922 - 3928
12345